An atypical antipsychotic that is used for the treatment of schizophrenia, schizoaffective disorder, and bipolar disorder that will be discussed is quetiapine (trade name Seroquel). Clinical trials studying the mechanism which quetiapine acts on iontropic glutamate receptors in comparison to haloperidol a convention antipsychotic and clozapine which is also an atypical antipsychotic show significant differences in their effects on NMDA, glutamatergic, and AMPA receptors elucidating possible explanations for the absence of EPS in atypical antipsychotic symptoms. In an analysis observing the possible gene expression modulation in NMDA and AMPA receptors suggests that each antipsychotic has a different effect than typical/conventional antipsychotics
…show more content…
Lurasidone (trade name Latuda) is an atypical antipsychotic that was fully FDA approved in 2013 to treat multiple disorders including bipolar disorder and will be another atypical antipsychotic that is new to the treatment of many disorders in addition to its initial use in the managing of positive and negative schizophrenic symptoms (approval for schizophrenia treatment was passed by the FDA in 2010). Lurasidone has a high to moderate affinity for multiple binding sites that are exclusive to this drug though similar to other atypical antipsychotics (5HT7, 5HT1A, and α-2C in addition to high affinity as a partial agonist to 5HT1A) (Deckersbach, 2015). The highest affinity for an antagonistic effect lurasidone contains is a distinctive trait and works on the 5HT7 which presents an interesting array of noted therapeutic possibilities. Not only is lurasidone an effective antidepressant and antipsychotic, it also possibly possesses low levels of cognitive enhancing properties (Stahl, 2013). Another advantage of lurasidone is its low histamine and acetylcholine affinities which lessens adverse effects such as weight gain, drowsiness, and intensified cognitive deficits (Nolan,
Lurasidone (trade name Latuda) is an atypical antipsychotic that was fully FDA approved in 2013 to treat multiple disorders including bipolar disorder and will be another atypical antipsychotic that is new to the treatment of many disorders in addition to its initial use in the managing of positive and negative schizophrenic symptoms (approval for schizophrenia treatment was passed by the FDA in 2010). Lurasidone has a high to moderate affinity for multiple binding sites that are exclusive to this drug though similar to other atypical antipsychotics (5HT7, 5HT1A, and α-2C in addition to high affinity as a partial agonist to 5HT1A) (Deckersbach, 2015). The highest affinity for an antagonistic effect lurasidone contains is a distinctive trait and works on the 5HT7 which presents an interesting array of noted therapeutic possibilities. Not only is lurasidone an effective antidepressant and antipsychotic, it also possibly possesses low levels of cognitive enhancing properties (Stahl, 2013). Another advantage of lurasidone is its low histamine and acetylcholine affinities which lessens adverse effects such as weight gain, drowsiness, and intensified cognitive deficits (Nolan,